Lifestyle
- Manage stress through mindfulness or meditation
- Ensure adequate sleep
- Engage in regular moderate exercise
Immunoglobulin A · IgA · Salivary IgA
IgA measures the concentration of immunoglobulin A antibodies in the blood or saliva, reflecting mucosal immune function.
Reference ranges may vary slightly by laboratory; consider age and sex-specific differences.
Immunoglobulin A (IgA) is a crucial antibody in the immune system, primarily found in mucous membranes lining the respiratory and gastrointestinal tracts, as well as in saliva, tears, and breast milk. It plays a vital role in mucosal immunity by preventing pathogens from adhering to and penetrating epithelial cells. Researchers have found that IgA is involved in immune defense mechanisms, particularly in neutralizing toxins and pathogens at mucosal surfaces. Clinically, IgA levels are significant in diagnosing and monitoring conditions such as IgA nephropathy, an autoimmune kidney disease characterized by IgA deposits in the glomeruli, leading to chronic kidney damage. Elevated IgA levels can also be indicative of liver disease, chronic infections, and certain autoimmune disorders, while low levels may suggest immunodeficiency. In the context of athletic performance and biohacking, IgA is relevant as it can reflect the body's immune response to stress and physical exertion. Athletes may monitor IgA levels to assess recovery and immune function, as intense exercise can transiently suppress IgA production, potentially increasing susceptibility to infections. However, researchers observed that IgA levels can be influenced by various factors, including stress, nutrition, and hydration status. Time-of-day variations and recent physical activity can also affect IgA measurements, necessitating consistent testing conditions for accurate monitoring. As such, IgA testing should be interpreted with caution, considering these potential confounders.
Klinische Bedeutung
Elevated IgA levels may indicate autoimmune conditions like IgA nephropathy, liver disease, or chronic infections. Reduced IgA levels can suggest immunodeficiency or increased susceptibility to infections.
Rising IgA levels may suggest worsening of autoimmune conditions or chronic infections; retest in 4-6 weeks to confirm trend.
Falling IgA levels could indicate improvement in underlying conditions or potential immunodeficiency.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any new supplement regimen, especially if you have underlying health conditions.
IgA levels can fluctuate throughout the day; consistent timing is recommended for repeat tests.
Testing Frequency
Annually for general health monitoring; more frequently if monitoring specific conditions.
May affect
Current research suggests that reference ranges and optimal targets for immunoglobulin A (IgA) levels in various clinical contexts, such as IgA nephropathy and stress response, remain inadequately defined. Researchers have not yet established the confounding factors that may influence IgA measurements, particularly in diverse populations. Additionally, clinical questions regarding the predictive value of IgA as a biomarker for disease progression and treatment response in autoimmune conditions remain unanswered.
1,170
Total Citations
15
Human/RCT
6.8
Avg. Influence
2025
Latest
This study investigated the effects of L-Theanine on stress responses, finding that it significantly reduced heart rate and salivary immunoglobulin A (s-IgA) during a stress task compared to a placebo. Researchers observed that these reductions were likely due to decreased sympathetic nervous system activation. The findings suggest potential anti-stress benefits of L-Theanine.
Researchers examined immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis, which can lead to chronic kidney disease in up to 40% of patients. They found significant variability in disease progression and outcomes across different populations, and noted the lack of specific biomarkers for diagnosis. Current treatments are limited, but new therapeutic approaches are being tested in clinical trials.
Researchers identified that gut microbiota-specific IgA+ B cells can traffic to the central nervous system (CNS) in multiple sclerosis (MS). The study found a strong IgA enrichment in active MS, suggesting a role for IgA in neuroinflammation. This highlights the potential of IgA as a biomarker for MS.
This study examined immunoglobulin A (IgA) deficiency, the most common primary immunoglobulin deficiency, and its association with infections and autoimmune diseases. Researchers noted that while many individuals are asymptomatic, those with symptoms often experience severe infections.
In a clinical trial, researchers evaluated the effects of Telitacicept on biomarkers in patients with immunoglobulin A nephropathy (IgAN). They observed significant reductions in galactose-deficient IgA1 and IgA-containing immune complexes, which correlated with decreased proteinuria. The findings suggest potential biomarkers for monitoring treatment response.
Researchers identified immunoglobulin A (IgA) antibodies against myelin oligodendrocyte glycoprotein (MOG) in a subgroup of patients with central nervous system demyelination. This finding suggests that MOG-IgA may serve as a novel diagnostic biomarker for certain demyelinating diseases.
Researchers explored the role of microscopic hematuria as a potential risk factor for progression in immunoglobulin A nephropathy (IgAN). The study discussed the challenges in standardizing hematuria assessments and called for its inclusion in clinical decision-making to guide treatment strategies in IgAN.
This study reported two cases of IgA vasculitis following COVID-19 vaccination, highlighting the potential for vaccines to trigger this condition. Researchers noted that both patients responded well to treatment with prednisolone, resolving their symptoms quickly.
Researchers highlighted the role of immunoglobulin A (IgA) in the immune response to SARS-CoV-2 infection, noting its significance as a diagnostic and prognostic marker. The study emphasized the potential of IgA detection tests for early diagnosis and treatment of COVID-19.
Researchers reviewed the molecular pathogenesis of immunoglobulin A nephropathy (IgAN) and introduced a new 'spiral hypothesis' to explain its chronic nature. They highlighted the need for targeted therapies and defined specific remission endpoints for treatment. The review emphasizes the importance of personalized treatment strategies based on biomarkers.
Research publications about Immunglobulin A over time
1totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer